ASHTON MCCRANIE: Open Payments
NPI 1386487890 · AUGUSTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,000 in 112 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $320 · 2025 $2,000
Food & beverage: $2,000
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $340 |
| ABBVIE INC. | 18 | $305 |
| AstraZeneca Pharmaceuticals LP | 15 | $293 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $160 |
| PFIZER INC. | 7 | $150 |
| GlaxoSmithKline, LLC. | 6 | $102 |
| Lilly USA, LLC | 4 | $90 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $80 |
| Abbott Laboratories | 4 | $77 |
| Novartis Pharmaceuticals Corporation | 3 | $73 |
Products named: Ozempic, Kerendia, FARXIGA, VRAYLAR, LINZESS, REXULTI, AIRSUPRA, MOUNJARO.
Industry payments across GA — which companies pay providers there.
